Related Experiment Video
Updated: Dec 28, 2025
09:01
Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
755
Invasive breast cancer: Current perspectives and emerging views
Eric Ka Ho Shea1,2, Valerie Cui Yun Koh2, Puay Hoon Tan3
1Department of Clinical Pathology, Tuen Mun Hospital, Tuen Mun, Hong Kong.
Pathology International
|February 11, 2020
Summary
This review details updates in invasive breast cancer classification, incorporating new histological entities and genetic insights. It highlights the evolving understanding of breast cancer pathogenesis and prognostic parameters.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Invasive breast cancer is a heterogeneous disease with diverse histological types.
- Current classification relies mainly on histopathology, with Invasive Carcinoma of No Special Type being most common.
- Emerging research focuses on genetic insights and the tumor microenvironment's role.
Purpose of the Study:
- To review updates in invasive breast cancer classification.
- To discuss new histological entities and genetic findings.
- To explore the role of tumor-infiltrating lymphocytes.
Main Methods:
- Review of current literature and recent advances in breast cancer research.
- Analysis of histopathological features and genetic alterations.
- Incorporation of the latest World Health Organization classification guidelines.
Main Results:
- The latest WHO classification integrates histologic and genetic findings.
- Medullary carcinomas are now part of Invasive Carcinoma of No Special Type with specific features.
- Tall cell carcinoma with reversed polarity is proposed as a distinct entity due to IDH2 mutations.
Conclusions:
- Breast cancer classification is evolving with new genetic and histopathological insights.
- Understanding tumor-infiltrating lymphocytes and the microenvironment is crucial.
- Updated classifications improve prognostic and predictive accuracy.
Related Concept Videos
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
02:30Metastasis
6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
03:03mTOR Signaling and Cancer Progression
4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.5K
02:07Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
01:30Cancer Vaccines
880
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
880